RecruitingPhase 3

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

China390 participantsStarted 2025-09-18

Plain-language summary

This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subject voluntarily takes part in the study after being fully informed,signs a written ICF, and agrees to follow procedures specified in the study protocol;
✓. Plaque psoriasis assessed by the investigator as suitable for systemic treatment and stable (defined as stable as no significant outbreak of morphological change or disease activity assessed by the investigator) for at least 6 months prior to signing informed consent;
✓. During the screening period and before taking the investigational drug for the first time, psoriatic surface area (BSA) ≥10%, PGA score ≥ 3, PASI score ≥ 12;
✓. Hematology, Blood chemistry and Urinalysis examination were basically normal.

✕. Erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, reverse psoriasis, drug-induced psoriasis;
✕. Have other skin lesions that affect the evaluation of treatment outcomes, such as eczema;
✕. History of herpes zoster/herpes simplex, or presence of herpes zoster/herpes simplex infection during the screening period;
✕. Have a history of tuberculosis, or active tuberculosis, or latent tuberculosis, or suspected clinical manifestations of tuberculosis infection;
✕. Other conditions that the investigator considers inappropriate for participation in the study.

The percentage of subjects with at least 90% improvement in PASI

Timeframe: Day 1-Day 112

NCT IDNCT07130604

SponsorInventisBio Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-07-28

Nan Tang

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subject voluntarily takes part in the study after being fully informed,signs a written ICF, and agrees to follow procedures specified in the study protocol;
✓. Plaque psoriasis assessed by the investigator as suitable for systemic treatment and stable (defined as stable as no significant outbreak of morphological change or disease activity assessed by the investigator) for at least 6 months prior to signing informed consent;
✓. During the screening period and before taking the investigational drug for the first time, psoriatic surface area (BSA) ≥10%, PGA score ≥ 3, PASI score ≥ 12;
✓. Hematology, Blood chemistry and Urinalysis examination were basically normal.

✕. Erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, reverse psoriasis, drug-induced psoriasis;
✕. Have other skin lesions that affect the evaluation of treatment outcomes, such as eczema;
✕. History of herpes zoster/herpes simplex, or presence of herpes zoster/herpes simplex infection during the screening period;
✕. Have a history of tuberculosis, or active tuberculosis, or latent tuberculosis, or suspected clinical manifestations of tuberculosis infection;
✕. Other conditions that the investigator considers inappropriate for participation in the study.